Event Description
Topic
Where We Are Since MR. CLEAN
Hosted By
Drexel Neurosciences Institute
Speaker
Erol Veznedaroglu MD, FAANS, FACS, FAHA, director, Drexel Neurosciences Institute
Learning Objectives
- Discuss the history of mechanical thrombectomy for stroke and initial clinical trials
- Discuss the current technology and data supporting current indications for mechanical thrombectomy
- Discuss the preliminary results of the ongoing DAWN trial and implications for the future of mechanical thrombectomy
Target Audience
DUCoM faculty, all physicians, fellows, residents, medical students, PAs, CRNPs, RNs; all medical specialties
Continuing Medical Education Credits
Drexel University College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA Credit Designation Statement: The Drexel University College of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
AOA: This program is eligible for 1 credits in Category 2A of the American Osteopathic Association.
Disclosure
Speakers at continuing medical education activities are required to disclose to the audience, any relevant commercial interest (which is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients). Any conflicts of interest must be resolved prior to the presentation and announced to the audience.
Dr. Veznedaroglu has disclosed his commercial relationship to Penumbra, Stryker Corporation and Trice as a consultant and will change his presentation to eliminate relevance to and refrain from recommending heath care goods or services of his commercial interest as well as support his presentation and clinical recommendations with the “best available evidence” from the medical literature. |